Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guadecitabine and Durvalumab in Advanced HCC, Pancreatic, and Biliary Cancers
NCT03257761Phase 1Active, not recruiting
- Sponsor
- University of Southern California
- Start
- Feb 2018
- Primary completion
- Sep 2021
- Modality
- Antibody Conjugates, DNA Intercalators/Alkylators, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of guadecitabine in hepatocellular carcinoma (HCC), pancreatic adenocarcinoma (PDAC), cholangiocarcinoma (CCA) and 1 more, sponsored by University of Southern California. Primary endpoints: Incidence of adverse events at 56 days and Objective Response Rate at 2 years. Started Feb 2018; status: active, not recruiting.
02
Drugs
guadecitabine
03
Conditions
hepatocellular carcinoma (HCC)pancreatic adenocarcinoma (PDAC)cholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on NCT03257761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03257761.